S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69
S&P 500   4,655.27
DOW   35,135.94
QQQ   399.69

Intra-Cellular Therapies Stock Forecast, Price & News

-1.52 (-3.58%)
(As of 11/29/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
639,079 shs
Average Volume
515,383 shs
Market Capitalization
$3.33 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive ITCI News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

Intra-Cellular Therapies logo

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc. operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. The firm's lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. It also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.


Intra-Cellular Therapies (NASDAQ:ITCI) Releases Earnings Results
November 11, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$22.81 million
Book Value
$5.98 per share


Net Income
$-227.01 million
Net Margins
Pretax Margin




Free Float
Market Cap
$3.33 billion

Company Calendar

Last Earnings
Fiscal Year End
Next Earnings (Estimated)


Overall MarketRank

2.40 out of 5 stars

Medical Sector

179th out of 1,392 stocks

Pharmaceutical Preparations Industry

75th out of 670 stocks

Analyst Opinion: 3.5Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

Intra-Cellular Therapies (NASDAQ:ITCI) Frequently Asked Questions

Is Intra-Cellular Therapies a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Intra-Cellular Therapies stock.
View analyst ratings for Intra-Cellular Therapies
or view top-rated stocks.

How has Intra-Cellular Therapies' stock been impacted by COVID-19 (Coronavirus)?

Intra-Cellular Therapies' stock was trading at $17.77 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ITCI shares have increased by 130.3% and is now trading at $40.93.
View which stocks have been most impacted by COVID-19

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decrease in short interest in October. As of October 29th, there was short interest totaling 4,210,000 shares, a decrease of 21.2% from the October 14th total of 5,340,000 shares. Based on an average trading volume of 441,200 shares, the days-to-cover ratio is presently 9.5 days. Currently, 5.8% of the company's stock are sold short.
View Intra-Cellular Therapies' Short Interest

When is Intra-Cellular Therapies' next earnings date?

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Intra-Cellular Therapies

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) released its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.92) by $0.03. The biopharmaceutical company had revenue of $22.21 million for the quarter, compared to analysts' expectations of $22.11 million. Intra-Cellular Therapies had a negative net margin of 367.06% and a negative trailing twelve-month return on equity of 44.88%. The company's revenue was up 201.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.79) EPS.
View Intra-Cellular Therapies' earnings history

What price target have analysts set for ITCI?

8 Wall Street analysts have issued 12-month price objectives for Intra-Cellular Therapies' shares. Their forecasts range from $38.00 to $70.00. On average, they expect Intra-Cellular Therapies' stock price to reach $49.71 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies
or view top-rated stocks among Wall Street analysts.

Who are Intra-Cellular Therapies' key executives?

Intra-Cellular Therapies' management team includes the following people:
  • Sharon Mates, Chairman, President & Chief Executive Officer
  • Lawrence J. Hineline, Chief Financial Officer, Treasurer & SVP-Finance
  • Robert E. Davis, Chief Scientific Officer & Senior Vice President
  • Suresh Durgam, Chief Medical Officer & Senior Vice President
  • Karen Patruno Sheehy, Chief Compliance Officer & Senior Vice President

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Who are Intra-Cellular Therapies' major shareholders?

Intra-Cellular Therapies' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Wasatch Advisors Inc. (9.99%), BlackRock Inc. (7.05%), Bellevue Group AG (4.64%), Marshall Wace LLP (2.82%), Lord Abbett & CO. LLC (2.57%) and TimesSquare Capital Management LLC (2.11%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates and Suresh K Durgam.
View institutional ownership trends for Intra-Cellular Therapies

Which major investors are selling Intra-Cellular Therapies stock?

ITCI stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Invesco Ltd., Schroder Investment Management Group, Goldman Sachs Group Inc., Lord Abbett & CO. LLC, Jaffetilchin Investment Partners LLC, Franklin Street Advisors Inc. NC, and Avestar Capital LLC. Company insiders that have sold Intra-Cellular Therapies company stock in the last year include Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Sharon Mates, and Suresh K Durgam.
View insider buying and selling activity for Intra-Cellular Therapies
or view top insider-selling stocks.

Which major investors are buying Intra-Cellular Therapies stock?

ITCI stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., TimesSquare Capital Management LLC, Brandywine Global Investment Management LLC, Credit Suisse AG, Suvretta Capital Management LLC, Candriam Luxembourg S.C.A., Bellevue Group AG, and Russell Investments Group Ltd..
View insider buying and selling activity for Intra-Cellular Therapies
or or view top insider-buying stocks.

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $40.93.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies has a market capitalization of $3.33 billion and generates $22.81 million in revenue each year. The biopharmaceutical company earns $-227.01 million in net income (profit) each year or ($3.21) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

Intra-Cellular Therapies employs 383 workers across the globe.

What is Intra-Cellular Therapies' official website?

The official website for Intra-Cellular Therapies is www.intracellulartherapies.com.

Where are Intra-Cellular Therapies' headquarters?

Intra-Cellular Therapies is headquartered at 430 EAST 29TH STREET, NEW YORK NY, 10016.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at [email protected], or via fax at 646-440-9334.

This page was last updated on 11/30/2021 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.